Nkarta reports Q3 EPS (29c), consensus (30c)

“This quarter marks an important milestone for Nkarta (NKTX) as we advance the NKX019 clinical program to treat autoimmune diseases,” said Paul Hastings, CEO of Nkarta. “Following productive engagement with the FDA, we streamlined enrollment across our Ntrust-1 and Ntrust-2 clinical trials under a combined iDSMB, which has authorized initiation of the second dose-escalation cohort. This unified approach, combined with the ability to dose multiple patients simultaneously at each dose level and the removal of a patient-by-patient stagger, strengthens the efficiency of our trial enrollment and underscores the consistency of NKX019’s emerging safety profile.”